Axcura AG is a Swiss life-science partner supporting regulated pharmaceutical and biopharmaceutical supply chains. We combine qualified sourcing of APIs, excipients, intermediates and biopharma ingredients with ISO 9001 quality management, PIC/S GDP distribution and audit-ready documentation.
Products, services, technology
Active Pharmaceutical Ingredients, BioPharma Ingredients, Excipients & Formulation, Intermediates & Chemicals. Services: strategic sourcing, custom manufacturing, PIC/S GDP supply-chain solutions, and two qualification programs — Trusted Goods (TG) and PureOne (analytical release).
Cooperation possibilities
We partner with innovators, generic manufacturers, CMOs and CDMOs across Europe — from early development through commercial supply. Typical collaborations: qualified sourcing and supplier assessment, scoped custom manufacturing, and documentation packages that withstand regulatory audits.
- https://www.axcura.com/
- +41 55 422 01 01
- Send an email
- Christoph Zahner
Some insights
Medicines only reach patients if the materials behind them are trustworthy. Axcura qualifies every API, Excipient and Biopharma ingredient it supplies, with documented traceability - so manufacturers can rely on continuity of supply, and patients on continuity of care.
That a small Swiss team holds itself to standards usually reserved for large manufacturers. Every material follows a defined qualification path - from document-based assessment to independent analytical release - and we never ship what we cannot document.
Organisations that pair scientific rigour with regulatory honesty: Swiss innovators who publish what they find, quality-driven CDMOs that refuse shortcuts, and suppliers who treat documentation as a promise rather than paperwork.
Our strength is depth where it counts: life-science sourcing, quality and regulatory expertise, and hands-on supplier qualification. We want to add analytical and bioprocessing depth, plus digital supply-chain tools that make traceability faster to prove.
That I make sure the right ingredient reaches the right factory at the right time, so the medicine someone needs actually gets made. Less glamorous than it sounds - mostly documents, audits and phone calls.
By bringing suppliers into the conversation earlier. Supply-chain and regulatory questions often surface late in development, when the options are expensive. Forums where innovators, manufacturers and suppliers meet early would strengthen resilience for everyone.
Procurement, QA and regulatory teams at biotech innovators, generic manufacturers, CMOs and CDMOs who need qualified raw materials with audit-ready documentation. We are equally keen to meet API and excipient manufacturers seeking a Swiss partner for European market access.
